Paper in NEJM of May 12 mentions leronlimab AS AN
Post# of 148168
"The antiviral drugs, such as Selzentry (maraviroc) and Leronlimab (PRO 140), have been successfully used for treatment of AIDS. It is therefore of great interest to study whether these drugs can block cardiac infiltration of CD8+ T cells thereby reduce hypertensive cardiac injury of COVID-19 patients."
https://www.nature.com/articles/s41423-020-0454-3
CytoDyn Inc (CYDY) Stock Research Links
Le-Ron-Li-Mab, and they have not.